ag-120

Myeloproliferative Neoplasm

M.D. Anderson Cancer CenterPhase 2Active

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 51/ 100
Competitive Position: 81/ 100

Competitive context

79 Active assets in the Myeloproliferative Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Evomela Center for International Blood and Marrow Transplant Research	Phase 2/3	BBB
Fludarabine Sawa Ito, MD	Phase 4	BB
Busulphan Sawa Ito, MD	Phase 4	BB
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center	Phase 2/3	BB
Fludarabine Sawa Ito, MD	Phase 4	BB

View all 50 →

Same molecule, other indications

ag-120 is also rated in:

acute myeloid leukemia with multilineage dysplasiaDormant

BB

Indicative ·

66 / 100

IDH1 MutationDormant

BB

Indicative ·

64 / 100

acute myeloid leukemiaDormant

B

Indicative ·

61 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.